125 related articles for article (PubMed ID: 9719457)
21. Functional analysis of P-glycoprotein and multidrug resistance associated protein related multidrug resistance in AML-blasts.
Brügger D; Herbart H; Gekeler V; Seitz G; Liu C; Klingebiel T; Orlikowsky T; Einsele H; Denzlinger C; Bader P; Niethammer D; Beck JF
Leuk Res; 1999 May; 23(5):467-75. PubMed ID: 10374860
[TBL] [Abstract][Full Text] [Related]
22. ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.
Raaijmakers MH; de Grouw EP; van der Reijden BA; de Witte TJ; Jansen JH; Raymakers RA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3452-8. PubMed ID: 16740770
[TBL] [Abstract][Full Text] [Related]
23. Single-cell image analysis to assess ABC-transporter-mediated efflux in highly purified hematopoietic progenitors.
Raaijmakers HG; Van Den Bosch G; Boezeman J; De Witte T; Raymakers RA
Cytometry; 2002 Dec; 49(4):135-42. PubMed ID: 12454976
[TBL] [Abstract][Full Text] [Related]
24. Molecular identification and functional characterization of Mdr1a in rat cholangiocytes.
Gigliozzi A; Fraioli F; Sundaram P; Lee J; Mennone A; Alvaro D; Boyer JL
Gastroenterology; 2000 Oct; 119(4):1113-22. PubMed ID: 11040198
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cell-mediated cytolysis and P-glycoprotein function in natural killer cells by verapamil isomers and cyclosporine A analogs.
Klimecki WT; Taylor CW; Dalton WS
J Clin Immunol; 1995 May; 15(3):152-8. PubMed ID: 7559918
[TBL] [Abstract][Full Text] [Related]
26. Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.
Ahmed-Belkacem A; Pozza A; Muñoz-Martínez F; Bates SE; Castanys S; Gamarro F; Di Pietro A; Pérez-Victoria JM
Cancer Res; 2005 Jun; 65(11):4852-60. PubMed ID: 15930306
[TBL] [Abstract][Full Text] [Related]
27. P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway.
Pallis M; Russell N
Blood; 2000 May; 95(9):2897-904. PubMed ID: 10779437
[TBL] [Abstract][Full Text] [Related]
28. Chemosensitization and drug accumulation assays as complementary methods for the screening of multidrug resistance reversal agents.
Quesada AR; Barbacid MM; Mira E; Aracil M; Márquez G
Cancer Lett; 1996 Jan; 99(1):109-14. PubMed ID: 8564921
[TBL] [Abstract][Full Text] [Related]
29. Reversal of multidrug resistance by B859-35, a metabolite of B859-35, niguldipine, verapamil and nitrendipine.
Hofmann J; Wolf A; Spitaler M; Böck G; Drach J; Ludescher C; Grunicke H
J Cancer Res Clin Oncol; 1992; 118(5):361-6. PubMed ID: 1349891
[TBL] [Abstract][Full Text] [Related]
30. Drug resistance in multiple myeloma: cyclosporin A analogues and their metabolites as potential chemosensitizers.
Pilarski LM; Yatscoff RW; Murphy GF; Belch AR
Leukemia; 1998 Apr; 12(4):505-9. PubMed ID: 9557608
[TBL] [Abstract][Full Text] [Related]
31. Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
Pallis M; Turzanski J; Langabeer S; Russell NH
Adv Exp Med Biol; 1999; 457():77-88. PubMed ID: 10500783
[TBL] [Abstract][Full Text] [Related]
32. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
33. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance.
Gekeler V; Boer R; Uberall F; Ise W; Schubert C; Utz I; Hofmann J; Sanders KH; Schächtele C; Klemm K; Grunicke H
Br J Cancer; 1996 Sep; 74(6):897-905. PubMed ID: 8826855
[TBL] [Abstract][Full Text] [Related]
34. P-glycoprotein-mediated multidrug resistance is modulated by pretreatment with chemosensitizers in HCT-8 carcinoma cells in vitro.
Haberl I; Swatonek H; Schaufler K; Ulsperger E; Wenzl E; Theyer G; Hamilton G; Thalhammer T
Int J Oncol; 1998 May; 12(5):1137-42. PubMed ID: 9538140
[TBL] [Abstract][Full Text] [Related]
35. Flow cytometric assay of modulation of P-glycoprotein function in whole blood by the multidrug resistance inhibitor GG918.
Witherspoon SM; Emerson DL; Kerr BM; Lloyd TL; Dalton WS; Wissel PS
Clin Cancer Res; 1996 Jan; 2(1):7-12. PubMed ID: 9816083
[TBL] [Abstract][Full Text] [Related]
36. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.
Warmann S; Göhring G; Teichmann B; Geerlings H; Fuchs J
J Pediatr Surg; 2002 Nov; 37(11):1579-84. PubMed ID: 12407543
[TBL] [Abstract][Full Text] [Related]
37. Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
Ludescher C; Hilbe W; Eisterer W; Preuss E; Huber C; Gotwald M; Hofmann J; Thaler J
J Natl Cancer Inst; 1993 Nov; 85(21):1751-8. PubMed ID: 8105101
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia.
van der Kolk DM; de Vries EG; van Putten WJ; Verdonck LF; Ossenkoppele GJ; Verhoef GE; Vellenga E
Clin Cancer Res; 2000 Aug; 6(8):3205-14. PubMed ID: 10955805
[TBL] [Abstract][Full Text] [Related]
39. Detection of P glycoprotein activity on normal and leukemic CD34+ cells.
Drenou B; Fardel O; Amiot L; Fauchet R
Leuk Res; 1993 Dec; 17(12):1031-5. PubMed ID: 7504150
[TBL] [Abstract][Full Text] [Related]
40. Both Pgp and MRP1 activities using calcein-AM contribute to drug resistance in AML.
Legrand O; Simonin G; Perrot JY; Zittoun R; Marie JP
Adv Exp Med Biol; 1999; 457():161-75. PubMed ID: 10500791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
